Fenebrutinib significantly reduced brain lesions in relapsing MS: Trial Therapy is a BTK enzyme inhibitor, working against B-cells and microglia
Genentech‘s investigational BTK inhibitor fenebrutinib significantly reduced the number of new brain lesions and showed no new safety concerns in people with relapsing forms of multiple sclerosis (MS).
That’s according to new data from the company’s Phase 2 FENopta clinical trial (NCT05119569), which is evaluating fenebrutinib’s safety, effectiveness, and pharmacokinetics (how a medication moves throughout the body) in 109 MS adults, ages 18-55. “I am encouraged by this clinical data for fenebrutinib, which is important news for people living with MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in a company press release.
Fenebrutinib is an investigational oral inhibitor of the Bruton’s tyrosine kinase (BTK) enzyme, which is essential for the inflammatory activity of B-cells and microglia — two immune cell types that contribute to inflammation in relapsing and progressive forms of MS.
A number of other BTK inhibitors are in development, including Novartis’ remibrutinib, Merck KGaA’s evobrutinib, and Sanofi’s tolebrutinib. Fenebrutinib is uniquely designed to bind its target in a reversible manner, making it safer than other therapies of the same class, however. It also seems to have fewer off-targets than the other therapies and is 130 times more selective against BTK than against similar enzymes.
“Fenebrutinib’s mechanism of action, which can inhibit both B cells and microglia, has the potential to both reduce MS disease activity, such as relapses, and also impact disease progression,” Garraway said.
Complete story:
https://multiplesclerosisnewstoday.c...lesions-trial/
Genentech‘s investigational BTK inhibitor fenebrutinib significantly reduced the number of new brain lesions and showed no new safety concerns in people with relapsing forms of multiple sclerosis (MS).
That’s according to new data from the company’s Phase 2 FENopta clinical trial (NCT05119569), which is evaluating fenebrutinib’s safety, effectiveness, and pharmacokinetics (how a medication moves throughout the body) in 109 MS adults, ages 18-55. “I am encouraged by this clinical data for fenebrutinib, which is important news for people living with MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in a company press release.
Fenebrutinib is an investigational oral inhibitor of the Bruton’s tyrosine kinase (BTK) enzyme, which is essential for the inflammatory activity of B-cells and microglia — two immune cell types that contribute to inflammation in relapsing and progressive forms of MS.
A number of other BTK inhibitors are in development, including Novartis’ remibrutinib, Merck KGaA’s evobrutinib, and Sanofi’s tolebrutinib. Fenebrutinib is uniquely designed to bind its target in a reversible manner, making it safer than other therapies of the same class, however. It also seems to have fewer off-targets than the other therapies and is 130 times more selective against BTK than against similar enzymes.
“Fenebrutinib’s mechanism of action, which can inhibit both B cells and microglia, has the potential to both reduce MS disease activity, such as relapses, and also impact disease progression,” Garraway said.
Complete story:
https://multiplesclerosisnewstoday.c...lesions-trial/